BioCardia (DB:6JU0) - Hisse Senedi Fiyatı, Haberler ve Analizler

6JU0 Stoklara Genel Bakış

A clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Daha fazla detay

6JU0 temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Gelirin yılda 71% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 7.8% oranında arttı

Risk Analizi

Negatif hissedar öz sermayesi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 13.7% oranında düşmesi öngörülüyor

Hisse senetleri oldukça likit değildir

Geliri 1 milyon ABD dolarından az ( $428K )

+ 3 daha fazla risk

BioCardia, Inc. Rakipler

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€20.6m

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Epigenomics

DB:ECX

€1.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti BioCardia
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$4.78
52 Haftanın En Yüksek Seviyesi	US$18.45
52 Haftanın En Düşük Seviyesi	US$0.15
Beta	1.36
11 Aylık Değişim	0%
3 Aylık Değişim	12.24%
1 Yıllık Değişim	-56.03%
33 Yıllık Değişim	-86.99%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-81.14%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	6JU0	DE Biotechs	DE Pazar
7D	0%	0.8%	0.8%
1Y	-56.0%	-18.3%	8.6%

Getiri vs. Endüstri: 6JU0 geçen yıl % -18.3 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 6JU0 geçen yıl % 8.6 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 6JU0's price volatile compared to industry and market?
6JU0 volatility
6JU0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 6JU0 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 6JU0 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	18	Peter Altman	www.biocardia.com

BioCardia, Inc. Temel Bilgiler Özeti

BioCardia'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
6JU0 temel i̇stati̇sti̇kler
Piyasa değeri	€5.27m
Kazançlar(TTM)	-€7.66m
Gelir(TTM)	€383.23k

13.7x

P/S Oranı

-0.7x

F/K Oranı

6JU0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
6JU0 gelir tablosu (TTM)
Gelir	US$428.00k
Gelir Maliyeti	US$5.07m
Brüt Kâr	-US$4.64m
Diğer Giderler	US$3.92m
Kazançlar	-US$8.56m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-4.03
Brüt Marj	-1,084.35%
Net Kâr Marjı	-1,999.77%
Borç/Özkaynak Oranı	0%

6JU0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

6JU0 Stoklara Genel Bakış

Ödüller

Risk Analizi

BioCardia, Inc. Rakipler

XTRA:CNW

€6.5m

XTRA:MDG1

€20.6m

BST:BPXA

€772.4k

DB:ECX

€1.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Regains Full Compliance with Nasdaq Capital Market's Listing Requirements

BioCardia, Inc. Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

BioCardia, Inc. Announces Fda Approves Cardiamp®? Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

BioCardia, Inc. Submits for FDA Approval of Morph®? DNA™? Steerable Introducer Product Family

Recent updates

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Regains Full Compliance with Nasdaq Capital Market's Listing Requirements

BioCardia, Inc. Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

BioCardia, Inc. Announces Fda Approves Cardiamp®? Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

BioCardia, Inc. Submits for FDA Approval of Morph®? DNA™? Steerable Introducer Product Family

BioCardia, Inc. Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

New major risk - Shareholder dilution

First quarter 2024 earnings released: US$0.09 loss per share (vs US$0.17 loss in 1Q 2023)

BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc., Annual General Meeting, May 20, 2024

Full year 2023 earnings released: US$0.55 loss per share (vs US$0.67 loss in FY 2022)

BioCardia, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement

BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

New major risk - Market cap size

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $2.75 million.

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.

BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.17 loss in 3Q 2022)

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

Biocardia, Inc. Announces Completion of Enrollment in Phase Iii Cardiamp Hf Trial and Plans for Cardiamp Hf Trial Ii

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia, Inc. Announces Clarification and Next Steps on Its Autologous CardiAMP Cell Therapy Programs

Biocardia, Inc. Announces Interim Efficacy Results in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

New major risk - Revenue size

Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.14 loss in 2Q 2022)

BioCardia, Inc. to Report First Half, 2023 Results on Aug 09, 2023

Biocardia, Inc. Announces Dsmb Recommendation to Pause New Enrollment in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial While Additional Blinded Data Is Collected

BioCardia, Inc. Completes Submission of Cardiamp Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

Insider recently bought €164k worth of stock

First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.20 loss in 1Q 2022)

BioCardia, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$0.67 loss per share (vs US$0.75 loss in FY 2021)

BioCardia, Inc. announced that it expects to receive $3.564989 million in funding

BioCardia, Inc. Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Insufficient new directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2021)

BioCardia, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Insufficient new directors

Biocardia®, Inc. to Present New Data from Cardiamp Cell Therapy for Heart Failure Pivotal Trial At the Heart Failure Society of America Annual Meeting

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.20 loss in 2Q 2021)

BioCardia, Inc. to Report First Half, 2022 Results on Aug 10, 2022

BioCardia, Inc. Announces US Patent on Imaging System for Targeting Cardiac Therapies

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.18 loss in 1Q 2021)

BioCardia, Inc. to Report Q1, 2022 Results on May 11, 2022

BioCardia, Inc. Announces FDA Approval of its IND for NK1R+ Mesenchymal Stem Cells

Full year 2021 earnings released: US$0.75 loss per share (vs US$1.48 loss in FY 2020)

Biocardia Receives No Objection Letter from Health Canada, Enabling Company to Expand Cardiamp Cell Therapy Heart Failure Trial into Canada